Within the U.S. Orthopedic Biomaterials market, multiple segments are discussed including bone graft substitutes, cellular allografts, and growth factors. Bone graft substitutes are designed to fill bone voids or act as extenders, thereby eliminating or decreasing the need for autograft harvesting. On the other hand, cellular allografts consist of allograft bone combined with adipose-derived mesenchymal stem cells, or what may be referred to as Human Cells, Tissues and Cellular and Tissue-based products (HCT/Ps), comprised of viable cells within a cortical cancellous bone matrix. Lastly, growth factors are naturally occurring proteins in the body that mediate a variety of cellular functions. These functions are tissue-specific, and regulation is a complex process.
iData’s recently completed MedSKU analysis includes an overview of the companies, products, and three segments discussed above. In addition, iData’s analysis includes metrics such as revenue, units sold, unit share, revenue share, and average selling prices (ASPs). Based on the data, the revenue and units sold experienced a sudden decline in Q2 ‘20, when COVID-19 hit. Despite this, certain companies were able to capitalize on the market opportunity and increase the number of units sold for specific brands into the third quarter of 2021.
MOST POPULAR U.S. ORTHOPEDIC BIOMATERIAL BRANDS PER SEGMENT
(based on the number of units sold in the third quarter of 2021)
Bone Graft Substitutes
- Stimulan Rapid Cure (Biocomposites)
- ReadiGraft Cancellous Chips (Lifenet)
Currently, in terms of units sold, Biocomposites leads the U.S. bone graft substitute segment with its Stimulan Rapid Cure device. Despite Biocomposites achieving the most units sold in Q3 ‘21, these numbers were slightly lower than those obtained in the previous quarter. Alternatively, Lifenet’s ReadiGraft Cancellous Chip device, which generated the second-most units sold, has seen a plateau since its peak in Q1 ‘21. Despite this, the overall market for bone graft substitutes is showing strong signs of growth. When COVID-19 hit in Q2 ‘20, the bone graft substitute market declined. However, by Q1 ‘21, the market had recovered significantly and has since been able to maintain this growth into Q3 ‘21.
- Vivigen Formable (Depuy Synthes)
- Trinity Elite (Orthofix)
When solely looking at units sold, Depuy Synthes has managed to take the lead within the cellular allograft market segment. Orthofix follows Depuy Synthes by approximately 5000 in terms of the most units sold. Despite Depuy Synthes’s success in Q3 ‘21, the number of units sold in Q3 ‘21 was significantly lower than the number of units sold in Q2 ‘21. Following the global COVID-19 pandemic, which caused a decline in Q2 ‘20, Depuy and its Vivigen Formable device were able to bounce back successfully in Q3 ‘20. Since Q3 ‘20, the number of Vivigen Formable units sold has remained relatively high until Q3 ‘21. Ironically the same trend holds true for Orthofix and the company’s Trinity Elite device as well. Additionally, when analyzing trends within the overall cellular allograft market, growth was observed from Q2 ‘20 into Q2 ‘21. Despite this, the overall market has since seen a drastic decline into Q3 ‘21, forcing the companies to re-evaluate their market strategies.
- Infuse Bone Graft (Medtronic)
- i-Factor Putty (Cerapedics)
Medtronic completely dominated and was able to take the lead within the growth factors market segment in terms of units sold for its Infuse Bone Graft device. Aside from this, Medtronic actually leads the entire orthobiologics market and the company’s share has remained relatively stable since 2019. Following by an extremely large margin is Cerapedics with its i-Factor Putty device. Since Q3 ‘20, Medtronic’s Infuse Bone Graft device has been increasing in a linear fashion aside from the slight decrease in Q3 ‘21. Similarly, Cerapedics i-Factor Putty device experienced growth from Q3 ‘20 into Q2 ‘21 before dropping slightly in Q3 ‘21. All in all, the overall growth factor market segment, despite facing a slightly lower Q3 ‘21, looks extremely strong and is still in the range to continue experiencing healthy growth into 2022.
MEDSKU: FURTHER INSIGHTS
The MedSKU solution allows you to: quantify the impact of COVID-19 on the market, understand the market response to new product launches and determine the most popular product configurations (brands, dimensions, materials, etc.), and answer specific questions like:
– How has the acquisition of Wright (by Stryker) in late 2020 affected the market?
– What are the most popular volumes of orthobiologics composites?
– How has the market recovered from COVID-19?
– Which competitors are falling behind due to the pandemic?